Clostridium Difficile Vaccine Candidate shows promising results in Phase II trials

Valneva SE, a leading pure-play vaccine company, announced Monday, positive Phase II results for its prophylactic vaccine candidate against Clostridium difficile (C. difficile) infection (CDI). The key objectives of this Phase II trial have been met, the vaccine candidate generated strong immune responses against C. difficile toxins A and B, and the safety and tolerability ["]